Saad Z. Usmani, MD, on The Challenges of Administering a New Triple Regimen in Myeloma

Posted: Wednesday, December 11, 2019

Saad Z. Usmani, MD, of the Levine Cancer Institute, discusses the logistics of ensuring adherence to the complex three-drug regimen of carfilzomib, dexamethasone, and daratumumab when the injectable agents are on different schedules and may cause different adverse events.